IART logo

INTEGRA LIFESCIENCES HOLDING

IARTNASDAQ
πŸ† #2422 by market capEarnings Feb 24 Β· PostUS Equity
$12.24β–² $0.26 (+2.13%)
Pre-market Β· at close
πŸ””
Track IART
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 2.1%
7dβ–Ό 0.6%
14dβ–Ό 9.5%
30dβ–Ό 26.5%
ytdβ–Ό 1.4%
1yβ–Ό 20.7%
🏦Market Cap
$952M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.8%
Slowing
πŸ“ŠGross Margin
56.8%
Healthy
πŸ’΅FCF Margin
2.2%
Thin
βš–οΈP/S Ratio
0.6x
Cheap
Otter Score
72
Strong

Trading Snapshot

Day Range
$11.94 – $12.32
52-Week Range
$8.70 – $20.49
Volume (shares)
118,876
Avg Volume (shares)
β€”
Shares Outstanding
77.8M
Next Earnings
2027-02-24

Fundamentals Snapshot

Annual Revenue
$1.64B
Last Q Revenue
$411M
P/E Ratio
72.1
P/S Ratio
0.6x
EPS (TTM)
$0.16
Dividend Yield
β€”
Dilution (1yr)
βˆ’0.3%
IART logo

INTEGRA LIFESCIENCES HOLDING

IART
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.6Bβ–² +1.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
51.7%β–Ό βˆ’5.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$68Mβ–² +140.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$45Mβ–Ό βˆ’281.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
76.8Mβ–Ό βˆ’0.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$1.8Bβ–Ό βˆ’$60M YoY
StockOtter Β· stockotter.space

About INTEGRA LIFESCIENCES HOLDING

Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
72/100

Analyst Ratings

β“˜
Consensus
Buy
18 analysts
Strong Buy4
Buy4
Hold8
Sell2
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.